Thomas Gibbs Recognized as 2024 PharmaVoice 100 Standout Leader
DEERFIELD, Ill. – Thomas Gibbs, Executive Vice President and President of Lundbeck U.S., has been named a 2024 PharmaVoice 100 honoree as a ‘Standout Leader’.
The PharmaVoice 100 annual list recognizes the most inspiring and transformative life sciences leaders driving positive impact at their companies, within their industry, and on behalf of the patients they serve.
“It’s a privilege to work in this industry and witness the positive impact and real difference our efforts can make for patients, families and communities,” said Gibbs. “Receiving this recognition is truly an honor, and it reflects the remarkable dedication of the Lundbeck US team that I am fortunate to lead. As a Focused Innovator in neuroscience, Lundbeck’s collective commitment to advancing brain health and transforming lives is unwavering. We strive to improve the lives of those affected by neurological and psychiatric diseases every day.”
Gibbs joined Lundbeck in February 2023 as an accomplished executive with more than 25 years of diverse corporate, general management and commercial leadership experience. This included roles in Executive Management, Marketing, Sales, Commercial Operations, Customer Insights and Analytics and Finance at small, mid-size and large pharmaceutical companies.
PharmaVoice100 honorees are selected from a pool of nominations submitted by readers and colleagues, evaluated by the PharmaVoice team, then categorized into 10 distinct groups. Each winner represents the transformative impact of the pharmaceutical industry in their own unique way.
“These honorees are inspirations. Their teams look to them for guidance, their patients for support, and their organizations for direction. Each winner represents progress toward a healthier future for everyone that is bolstered by science and technological advancements. We are excited to recognize their contributions through this annual list,” said Meagan Parrish, lead editor of PharmaVoice.
Since 2005, the PharmaVoice 100 has become one of the publication’s most anticipated features. From academia and nonprofits to Big Pharma, startups, and tech companies, it is the only awards program in the industry that honors individuals from all sectors of life sciences. These honorees, from the clinic to the C-suite, are making meaningful contributions to their fields and striving to improve outcomes for patients around the world.
About Lundbeck
Lundbeck is a global biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, we are committed to improving the lives of people with neurological and psychiatric diseases.
As a focused innovator, we strive for our research and development programs to tackle some of the most complex neurological challenges. We develop transformative medicines targeting people for whom there are few or no treatments available, expanding into neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology. We strive to create long-term value for our shareholders by making positive contributions to patients, their families and society as a whole.
Lundbeck US comprises the wholly owned US subsidiaries of H. Lundbeck A/S (HLUNa / HLUNb, HLUNA DC / HLUNB DC) (“Lundbeck”), including Lundbeck LLC and Lundbeck Pharmaceuticals LLC.
For additional information on Lundbeck US, please visit Lundbeck.com/us and connect with us on LinkedIn and X at @LundbeckUS.
About PharmaVoice
PharmaVoice is a leading industry publication operated by Industry Dive. Our stories deliver the most important voices and ideas in the life sciences to industry leaders.
About Industry Dive
Industry Dive, an Informa business, is a leading business journalism company. Over 14 million decision-makers across 20+ competitive industries rely on our exclusive insight and analysis delivered through more than 30 publications.